ライフサイエンスコーパス: cardiovascular morbidity

1 the several risk factors for CKD and related cardiovascular morbidity.

2 aired glucose tolerance, hyperlipidemia, and cardiovascular morbidity.

3 e relationship between caregiving stress and cardiovascular morbidity.

4 raction of heart and brain in stress-induced cardiovascular morbidity.

5 Low energy expenditure is a risk for cardiovascular morbidity.

6 ator-1 (PAI-1) are associated with long-term cardiovascular morbidity.

7 nts into three risk groups for mortality and cardiovascular morbidity.

8 tion that has been shown to be predictive of cardiovascular morbidity.

9 nts have also been associated with increased cardiovascular morbidity.

10 igh-sensitivity CRP are predictive of future cardiovascular morbidity.

11 lucidate the link between RBC dyscrasias and cardiovascular morbidity.

12 en found to have a protective effect against cardiovascular morbidity.

13 ence, which can be associated with increased cardiovascular morbidity.

14 hese antibodies correlate with mortality and cardiovascular morbidity.

15 isk for the development of a wide variety of cardiovascular morbidities.

16 hypoxia (CIH), and causally associates with cardiovascular morbidities.

17 tality similar to expected (P=0.20) but high cardiovascular morbidity (6.2%/y, P<0.01) and notable MV

18 despite its associations with higher risk of cardiovascular morbidity, accelerated cognitive decline

19 racteristics offers hope of reducing serious cardiovascular morbidity after HCT.

20 itors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial

21 Cytotoxic CD4 T cells are linked to cardiovascular morbidities and accumulate in both HIV an

22 cination against seasonal influenza prevents cardiovascular morbidity and all-cause mortality in pati

23 s populations as an independent predictor of cardiovascular morbidity and all-cause mortality.

24 s of this low-expression variant of FABP4 on cardiovascular morbidity and carotid atherosclerosis on

25 s more effective than atenolol in preventing cardiovascular morbidity and death, predominantly stroke

26 independent risk factor for kidney failure, cardiovascular morbidity and death.

27 ry hypertension (PH) is a key contributor to cardiovascular morbidity and early mortality; however, r

28 ey transplantation, complications, including cardiovascular morbidity and graft loss, contribute to r

29 a common complication of obesity, conferring cardiovascular morbidity and increased mortality and oft

30 Insulin resistance (IR) increases cardiovascular morbidity and is associated with mitochon

31 We evaluated cardiovascular morbidity and mortality according to the

32 itors, or statins, have been shown to reduce cardiovascular morbidity and mortality among a wide spec

33 ble therapies, there is a marked increase in cardiovascular morbidity and mortality among patients su

34 argets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons wit

35 intervention for weight loss would decrease cardiovascular morbidity and mortality among such patien

36 was associated with remarkable reduction of cardiovascular morbidity and mortality and all-cause dea

37 ociated with respiratory diseases as well as cardiovascular morbidity and mortality and can reduce lu

38 ion have been reported to be associated with cardiovascular morbidity and mortality and increased car

39 Air pollution exposure increases cardiovascular morbidity and mortality and is a major gl

40 rain is associated with an increased risk of cardiovascular morbidity and mortality and of all-cause

41 th most antihypertensive medications reduces cardiovascular morbidity and mortality and possibly cogn

42 rysms in HCM are associated with substantial cardiovascular morbidity and mortality and raise novel t

43 high risk for metabolic syndrome and related cardiovascular morbidity and mortality and require regul

44 Cardiovascular morbidity and mortality and shortened all

45 that this hyperactivity may explain delayed cardiovascular morbidity and mortality and that it arise

46 Cardiovascular morbidity and mortality are higher among

47 Data from observational studies suggest that cardiovascular morbidity and mortality are increased in

48 Cardiovascular morbidity and mortality are reduced by tr

49 Atherothrombosis is the leading cause of cardiovascular morbidity and mortality around the globe.

50 Cardiovascular morbidity and mortality as a result of in

51 ledge that could help address the increasing cardiovascular morbidity and mortality associated with a

52 nditions may be at increased risk of adverse cardiovascular morbidity and mortality associated with a

53 ith a high-sensitivity assay (hs-GH) predict cardiovascular morbidity and mortality at the population

54 represents a major risk factor not only for cardiovascular morbidity and mortality but also for cogn

55 ysfunction that is associated with increased cardiovascular morbidity and mortality caused by obesity

56 systolic blood pressure of 120 mm Hg reduces cardiovascular morbidity and mortality compared with a h

57 ibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity and mortality compared with ena

58 Heart failure-induced cardiovascular morbidity and mortality constitute a majo

59 x is independently associated with increased cardiovascular morbidity and mortality during progressio

60 nd-stage renal disease and limit or abrogate cardiovascular morbidity and mortality has led to increa

61 type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been dete

62 Cardiovascular morbidity and mortality have been found t

63 he past three decades, age-adjusted rates of cardiovascular morbidity and mortality have fallen in th

64 sity are predisposed to an increased risk of cardiovascular morbidity and mortality in adulthood.

65 ry behavior is associated with all-cause and cardiovascular morbidity and mortality in adults such th

66 index and increased glucose tolerance); and cardiovascular morbidity and mortality in adults without

67 or the combination had comparable effects on cardiovascular morbidity and mortality in African Americ

68 considered recently as potent predictors of cardiovascular morbidity and mortality in all explored p

69 and soft tissue calcification contributes to cardiovascular morbidity and mortality in both the gener

70 llance and therapeutics, ultimately reducing cardiovascular morbidity and mortality in cancer patient

71 tem remain prevalent and important causes of cardiovascular morbidity and mortality in developing cou

72 ctors fail to explain the increased risk for cardiovascular morbidity and mortality in ESRD.

73 heart disease and with an increased risk of cardiovascular morbidity and mortality in hypertensive p

74 e cotransporter 2 (SGLT2) inhibition reduces cardiovascular morbidity and mortality in individuals wi

75 failure of antioxidant therapy in preventing cardiovascular morbidity and mortality in major clinical

76 Statins reduce cardiovascular morbidity and mortality in many patients

77 cence genes have been associated with higher cardiovascular morbidity and mortality in nontransplant

78 appear to be an independent risk factor for cardiovascular morbidity and mortality in older women.

79 Low Hgb levels correlate with increased cardiovascular morbidity and mortality in patients prese

80 ary artery disease (CAD) is a major cause of cardiovascular morbidity and mortality in patients with

81 Statins significantly reduce cardiovascular morbidity and mortality in patients with

82 onstrated that medical therapy can attenuate cardiovascular morbidity and mortality in patients with

83 rials have shown that statin therapy reduces cardiovascular morbidity and mortality in patients with

84 Heart failure is a major contributor to cardiovascular morbidity and mortality in patients with

85 ors have a relatively lesser contribution to cardiovascular morbidity and mortality in patients with

86 nvestigated the effects of statin therapy on cardiovascular morbidity and mortality in patients with

87 esyl sulfate (PCS) have been associated with cardiovascular morbidity and mortality in patients with

88 m-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with

89 The high cardiovascular morbidity and mortality in patients with

90 e medical therapy is feasible and relates to cardiovascular morbidity and mortality in patients with

91 nsporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with

92 to develop effective interventions to reduce cardiovascular morbidity and mortality in RA patients.

93 Dyslipidemia is a risk factor for premature cardiovascular morbidity and mortality in renal transpla

94 y underlie cardiac dysfunction and increased cardiovascular morbidity and mortality in subjects with

95 ischemia and may contribute to the increased cardiovascular morbidity and mortality in such patients.

96 an independent and incremental predictor of cardiovascular morbidity and mortality in T2DM patients

97 rate has been shown to be a risk factor for cardiovascular morbidity and mortality in the general po

98 the prognostic utility of GLS for long-term cardiovascular morbidity and mortality in the general po

99 iographic monitoring is required to minimize cardiovascular morbidity and mortality in this specific

100 en the exposure to air pollution and overall cardiovascular morbidity and mortality is increasingly f

101 iovascular events, the accurate incidence of cardiovascular morbidity and mortality is unknown.

102 association of particulate matter (PM) with cardiovascular morbidity and mortality is well documente

103 hat individuals with schizophrenia have high cardiovascular morbidity and mortality is well establish

104 Whether this translates to lower cardiovascular morbidity and mortality long term is uncl

105 ay be a potential precursor of the increased cardiovascular morbidity and mortality observed in patie

106 and this has been associated with the excess cardiovascular morbidity and mortality observed in this

107 dence suggest that OSA increases the risk of cardiovascular morbidity and mortality partly via accele

108 antiplatelet medications, is known to reduce cardiovascular morbidity and mortality rates in these pa

109 Cardiovascular morbidity and mortality remain high in re

110 Cardiovascular morbidity and mortality resulting from co

111 yle Changes Diet are effective in decreasing cardiovascular morbidity and mortality risk, and such di

112 Peripheral arterial disease is a marker of cardiovascular morbidity and mortality risk.

113 ollutants over years confers higher risks of cardiovascular morbidity and mortality than shorter-term

114 et and physical activity have lower rates of cardiovascular morbidity and mortality than those who do

115 ealthy diet and physical activity have lower cardiovascular morbidity and mortality than those who do

116 0-75 years examined in 1989 and followed for cardiovascular morbidity and mortality through 2000 to a

117 B]) and QRS morphology in those with BBB, on cardiovascular morbidity and mortality was assessed by a

118 The predictive value of WRF on cardiovascular morbidity and mortality was examined duri

119 Cardiovascular morbidity and mortality were hypothesized

120 scular disease and is a significant cause of cardiovascular morbidity and mortality worldwide.

121 ructive sleep apnea (OSA) is associated with cardiovascular morbidity and mortality, although the und

122 Reduced kidney function is a risk factor for cardiovascular morbidity and mortality, and both heart f

123 failure is one of the most common causes of cardiovascular morbidity and mortality, and hypertension

124 common in women, is associated with adverse cardiovascular morbidity and mortality, and is a major b

125 left ventricular hypertrophy (LVH) predicts cardiovascular morbidity and mortality, and regression o

126 ween exposure to fine particulate matter and cardiovascular morbidity and mortality, and that fine pa

127 are not only epidemiologically connected to cardiovascular morbidity and mortality, but can also be

128 iation of depression and phobic anxiety with cardiovascular morbidity and mortality, but little is kn

129 lution has been consistently associated with cardiovascular morbidity and mortality, but mechanisms r

130 dothelial dysfunction and increased risk for cardiovascular morbidity and mortality, but the state of

131 Treating depression may have an impact on cardiovascular morbidity and mortality, but this has not

132 this guideline included all-cause mortality, cardiovascular morbidity and mortality, cerebrovascular

133 on has emerged as a significant predictor of cardiovascular morbidity and mortality, challenging prev

134 idelines-recommended therapies have impacted cardiovascular morbidity and mortality, endovascular int

135 ular calcification is highly associated with cardiovascular morbidity and mortality, especially in pa

136 ciated with 2.4- to 3.4-fold higher risks of cardiovascular morbidity and mortality, independent of e

137 Elevated levels of NT-proBNP predict cardiovascular morbidity and mortality, independent of o

138 iffness has independent prognostic value for cardiovascular morbidity and mortality, its predictors m

139 Unlike cardiovascular morbidity and mortality, little is known

140 ch has already been demonstrated to decrease cardiovascular morbidity and mortality, provides signifi

141 ough depression is associated with increased cardiovascular morbidity and mortality, there is virtual

142 The primary outcome, cardiovascular morbidity and mortality, was analysed by

143 ques, which are strong predictors for future cardiovascular morbidity and mortality, was higher in at

144 igh blood pressure (BP) is a risk factor for cardiovascular morbidity and mortality.

145 idemiological findings of increased risk for cardiovascular morbidity and mortality.

146 iabetes mellitus are a major risk factor for cardiovascular morbidity and mortality.

147 2.5 microm (PM2.5) has been associated with cardiovascular morbidity and mortality.

148 alternative regimens in an effort to reduce cardiovascular morbidity and mortality.

149 ween air pollution exposure and increases in cardiovascular morbidity and mortality.

150 ction patients at particularly high risk for cardiovascular morbidity and mortality.

151 t failure often coexist, causing substantial cardiovascular morbidity and mortality.

152 GH were associated with an increased risk of cardiovascular morbidity and mortality.

153 The primary outcome was a composite of cardiovascular morbidity and mortality.

154 sity lipoprotein cholesterol (LDL-C) reduces cardiovascular morbidity and mortality.

155 sult in clinically significant reductions in cardiovascular morbidity and mortality.

156 arction is a primary contributor to maternal cardiovascular morbidity and mortality.

157 rlipidemia, is a significant risk factor for cardiovascular morbidity and mortality.

158 PAD is associated with increased risk of cardiovascular morbidity and mortality.

159 ions between ambient O(3) concentrations and cardiovascular morbidity and mortality.

160 l activity are major factors contributing to cardiovascular morbidity and mortality.

161 ention and is associated with postprocedural cardiovascular morbidity and mortality.

162 tant hypertension that might result in lower cardiovascular morbidity and mortality.

163 ion may collectively contribute to increased cardiovascular morbidity and mortality.

164 structure and function were associated with cardiovascular morbidity and mortality.

165 azepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality.

166 which is associated with markedly increased cardiovascular morbidity and mortality.

167 age, is associated with an increased risk of cardiovascular morbidity and mortality.

168 as a mechanism by which active RA increases cardiovascular morbidity and mortality.

169 to identify novel strategies for preventing cardiovascular morbidity and mortality.

170 tion between preventive measures and reduced cardiovascular morbidity and mortality.

171 r extremity performance, and higher rates of cardiovascular morbidity and mortality.

172 lar calcification is a major risk factor for cardiovascular morbidity and mortality.

173 reatment of sleep apnea in the prevention of cardiovascular morbidity and mortality.

174 ance, and hypertension, is a risk factor for cardiovascular morbidity and mortality.

175 king on large longitudinal studies to assess cardiovascular morbidity and mortality.

176 Atherosclerosis remains the leading cause of cardiovascular morbidity and mortality.

177 syndromes and is associated with substantial cardiovascular morbidity and mortality.

178 ir pollutants are positively associated with cardiovascular morbidity and mortality.

179 adverse health effects, including increased cardiovascular morbidity and mortality.

180 -onset heart failure (HF) is associated with cardiovascular morbidity and mortality.

181 s been shown to be associated with increased cardiovascular morbidity and mortality.

182 ted by heart failure is associated with high cardiovascular morbidity and mortality.

183 nd incident ECG abnormalities with long-term cardiovascular morbidity and mortality.

184 nic kidney disease are at increased risk for cardiovascular morbidity and mortality.

185 ietary fiber appears to decrease the risk of cardiovascular morbidity and mortality.

186 latelet activation have successfully reduced cardiovascular morbidity and mortality.

187 ally to improve quality of life and decrease cardiovascular morbidity and mortality.

188 y the association of serum urate levels with cardiovascular morbidity and mortality.

189 sion remains the most common risk factor for cardiovascular morbidity and mortality.

190 end-stage renal disease are at high risk for cardiovascular morbidity and mortality.

191 tern societies, is associated with increased cardiovascular morbidity and mortality.

192 Vascular calcification is associated with cardiovascular morbidity and mortality.

193 (LDL) particles are a major risk factor for cardiovascular morbidity and mortality.

194 perience an acute MI might reduce subsequent cardiovascular morbidity and mortality.

195 Statins reduce serum cholesterol and cardiovascular morbidity and mortality.

196 d cardiomyopathy is now the leading cause of cardiovascular morbidity and mortality.

197 n this area as a major influence in reducing cardiovascular morbidity and mortality.

198 al disease (ESRD), and it has been linked to cardiovascular morbidity and mortality.

199 nge are associated with an increased risk of cardiovascular morbidity and mortality.

200 ugs reduce both atherogenic lipoproteins and cardiovascular morbidity and mortality.

201 iovascular stiffness as well as the risk for cardiovascular morbidity and mortality.

202 hazard, and it contributes significantly to cardiovascular morbidity and mortality.

203 mplementary management strategy for reducing cardiovascular morbidity and mortality.

204 , and arrhythmia, which clinically result in cardiovascular morbidity and mortality.

205 Left ventricular mass is a risk factor for cardiovascular morbidity and mortality.

206 -stage renal disease is associated with high cardiovascular morbidity and mortality.

207 ophy is associated with an increased risk of cardiovascular morbidity and mortality.

208 ures is associated with a marked increase in cardiovascular morbidity and mortality.

209 nts has been explored as a means of reducing cardiovascular morbidity and mortality.

210 ubgroups in the relation of sodium intake to cardiovascular morbidity and mortality.

211 Total mortality and cardiovascular morbidity and mortality.

212 and control measures to decrease associated cardiovascular morbidity and mortality.

213 and is associated with an increased risk of cardiovascular morbidity and mortality.

214 heart rate is significantly associated with cardiovascular morbidity and mortality.

215 ion between the level of serum uric acid and cardiovascular morbidity and mortality.

216 w-density lipoprotein cholesterol) to reduce cardiovascular morbidity and mortality.

217 alent modifiable risk factor associated with cardiovascular morbidity and mortality.

218 OSA leads to high cardiovascular morbidity and mortality.

219 ral artery disease have an increased risk of cardiovascular morbidity and mortality.

220 It is also linked with worse cardiovascular morbidity and mortality.

221 anagement of dyslipidemia can markedly alter cardiovascular morbidity and mortality.

222 lution and temperature have been linked with cardiovascular morbidity and mortality.

223 stic information regarding long-term risk of cardiovascular morbidity and mortality.

224 and is associated with significant limb and cardiovascular morbidity and mortality.

225 Diabetes mellitus is a major risk factor for cardiovascular morbidity and mortality.

226 n and canagliflozin have been shown to lower cardiovascular morbidity and mortality.

227 ifestyle-related risk factors (LRFs) reduces cardiovascular morbidity and mortality.

228 n the exercise volume and risk reductions in cardiovascular morbidity and mortality.

229 erial disease (PAD) are at increased risk of cardiovascular morbidity and mortality.

230 tients with diabetes mellitus to reduce both cardiovascular morbidity and mortality.

231 therosclerosis that is manifest by increased cardiovascular morbidity and mortality.

232 ness (CRF) is an independent risk factor for cardiovascular morbidity and mortality.

233 Hypertension contributes to cardiovascular morbidity and mortality.

234 ients undergoing hemodialysis contributes to cardiovascular morbidity and mortality.

235 rotic disease, and association with incident cardiovascular morbidity and mortality.

236 e, and it is a strong predictor of increased cardiovascular morbidity and mortality.

237 atherosclerosis, which may lead to increased cardiovascular morbidity and mortality.

238 nts with HFpEF at particularly high risk for cardiovascular morbidity and mortality.

239 ntify patients at particularly high risk for cardiovascular morbidity and mortality.

240 l artery disease (PAD) is a leading cause of cardiovascular morbidity and mortality; however, the ext

241 as been associated with an increased risk of cardiovascular morbidity and mortality; however, the ind

242 s is associated with increased prevalence of cardiovascular morbidity and mortality; however, the nat

243 calcium burden is a significant predictor of cardiovascular morbidity and mortality; however, the und

244 Obstructive sleep apnea causes cardiovascular morbidity and premature death.

245 albuminuria are also predictive of diabetes, cardiovascular morbidity, and death in nontransplanted p

246 hypertension, osteoporosis, central obesity, cardiovascular morbidity, and increased mortality.

247 recognized as playing a significant role in cardiovascular morbidity, and its role in hypertension h

248 associated with increased risk of mortality, cardiovascular morbidity, and major amputation.

249 lureas; the evidence on all-cause mortality, cardiovascular morbidity, and microvascular complication

250 t for the end points of all-cause mortality, cardiovascular morbidity, and mortality.

251 the progression to end-stage kidney failure, cardiovascular morbidity, and premature death.

252 nonwhite race, lower income, older age, less cardiovascular morbidity at initiation of therapy, depre

253 ars and postponed the onset of all-cause and cardiovascular morbidity by 4.5 and 7 years, respectivel

254 critical limb ischemia have a perioperative cardiovascular morbidity comparable to patients with acu

255 erview of the association between stress and cardiovascular morbidity, discuss the mechanisms for thi

256 This study compared mortality and cardiovascular morbidity during percutaneous coronary in

257 s the third leading cause of atherosclerotic cardiovascular morbidity, following coronary artery dise

258 tion in endothelial health and the long-term cardiovascular morbidity for children with primary syste

259 Cardiovascular morbidity has been associated with partic

260 1.16) or multivariable adjustment, including cardiovascular morbidities (hazard ratio, 0.94; 95% conf

261 ), was found to be associated with increased cardiovascular morbidity; however, another such drug, ce

262 fruit and vegetable consumption with reduced cardiovascular morbidity; however, there is little direc

263 des and contribute to thrombus formation and cardiovascular morbidities in HIV infection.

264 Their association with cardiovascular morbidity in addition to their suboptimal

265 evelops in childhood to decrease the risk of cardiovascular morbidity in adulthood.

266 are probably involved in the pathogenesis of cardiovascular morbidity in CCSs.

267 sma levels of TMAO, which is associated with cardiovascular morbidity in chronic kidney disease (CKD)

268 ion is identified as a major risk factor for cardiovascular morbidity in most larger population-based

269 The magnitude of cardiovascular morbidity in paediatric, adolescent, and

270 The true effect of cardiovascular morbidity in paediatric, adolescent, and

271 Higher cardiovascular morbidity in patients with a wide range o

272 mass (LVM) is associated with mortality and cardiovascular morbidity in patients with end-stage rena

273 ions in T cell lymphocytes may contribute to cardiovascular morbidity in pediatric OSA.

274 Statins reduce atherosclerosis and cardiovascular morbidity in the general population, but

275 ese and diabetic patients and contributes to cardiovascular morbidity in these disorders.

276 cesses associated with OSA may contribute to cardiovascular morbidity in these patients.

277 iatric surgery improves predictors of future cardiovascular morbidity in these young people.

278 DPP-4 inhibition has the potential to reduce cardiovascular morbidity in treated HIV infection.

279 sm (PA) is common and associates with excess cardiovascular morbidity independent of blood pressure.

280 idney transplant recipients, predicts future cardiovascular morbidity is unclear.

281 ot specifically powered to detect changes in cardiovascular morbidity, length of stay, or mortality.

282 ammatory condition associated with increased cardiovascular morbidity/mortality and an incompletely u

283 ammatory condition associated with increased cardiovascular morbidity/mortality and an incompletely u

284 or MDS, and, mechanistically, as a driver of cardiovascular morbidity/mortality in individuals with a

285 were mortality (n=96, 19+/-2% at 10 years), cardiovascular morbidity (n=171), and MVP-related events

286 r event, including cardiovascular mortality, cardiovascular morbidity (non-fatal myocardial infarctio

287 sleep complaints, short sleep duration, and cardiovascular morbidity observed in epidemiologic surve

288 ortality of 5+/-2% (P=0.17 versus expected), cardiovascular morbidity of 0.5%/y, and MVP-related even

289 These risk factors are often associated with cardiovascular morbidity or mortality and with total mor

290 There was no increased risk of cardiovascular morbidity or mortality associated with va

291 tazone does not increase the risk of overall cardiovascular morbidity or mortality compared with stan

292 hysiologic outcomes, diabetes incidence, and cardiovascular morbidity or mortality in adults with CVD

293 long-acting muscarinic antagonists increase cardiovascular morbidity or mortality in patients with c

294 obesity medication has been shown to reduce cardiovascular morbidity or mortality.

295 n individual's all-cause morbidity score and cardiovascular morbidity score were calculated from Inte

296 p apnea (OSA) in children is associated with cardiovascular morbidity such as systemic and pulmonary

297 Information on all-cause mortality and cardiovascular morbidity (such as the acute coronary syn

298 IGT is more predictive of cardiovascular morbidity than impaired fasting glucose,

299 Freedom from any cardiovascular morbidity was 88% at 15 years and 84% at

300 ary risk factors independently predictive of cardiovascular morbidity were slight mitral regurgitatio